Increased Expression of RCN1P2, TPM3P9, and HSP90AB3P as Non-Coding RNA in Gastric Cancer Linked to Proliferative, Inflammatory and Metastatic Pathways through a Competing Endogenous RNAs Network
-
Ensieh Sagheb Sadeghi
,
Zahra Amrollahy Bioky
,
Mahsa Hokmabadi
,
Samira Asadollahi
,
Fatemeh Sarhadi
,
Nasrin Fattahi Dolatabadi
,
Atefeh Zamani
,
Mohammad Mahdevar
,
Maryam Peymani
Abstract
Background: This study aimed to find pseudogenes with significant expression alterations in gastric cancer (GC) that could be implicated in the disease's development via the competing endogenous RNAs (ceRNAs) network.
Methods: Pseudogenes, mRNAs, and microRNAs, whose expression changes considerably in GC specimens, were identified using the Cancer Genome Atlas (TCGA) data from 2006 to 2017 (USA). The ceRNAs network was constructed using the miRWalk, miRTarBase, and DIANA-LncBase. The cox regression test was performed to assess the correlation between candidate genes and patient prognosis. Finally, using the RT-qPCR method, the in-silico results were evaluated using GC samples and adjacent normal. Samples were collected from Imam Khomeini Hospital in Tehran (Iran) between 2020 and 2021.
Results: In the cancer samples compared to the normal ones, there were 86 miRNAs, 1985 mRNAs, and 33 pseudogenes showing expression alterations, either more than or less than a twofold difference. Constructed ceRNA network demonstrated that pseudogenes such as RCN1P2, TPM3P9, and HSP90AB3P were most connected to changed mRNAs and microRNAs in GC. The analysis of the ceRNA network for each of the mentioned pseudogenes indicated that the associated mRNAs play roles in cell proliferation, inflammation, and metastatic pathways. Furthermore, elevated expression of several mRNAs linked to potential pseudogenes was linked to a poor prognosis. RT-qPCR revealed a significant increase in the expression levels of RCN1P2, TPM3P9, and HSP90AB3P in GC samples.
Conclusion: The expression of RCN1P2, TPM3P9, and HSP90AB3P is dramatically enhanced in GC. They can also influence the survival rate of GC patients by regulating pathways involved in cell proliferation, inflammation, and metastasis via the ceRNAs network.
2. Cho JY, Lim JY, Cheong JH, et al (2011). Gene expression signature–based prognostic risk score in gastric cancer. Clin Cancer Res, 17(7):1850-7.
3. Dorosti S, Jafarzadeh Ghoushchi S, Sobhrakhshankhah E, et al (2020). Application of gene expression programming and sensitivity analyses in analyzing effective parameters in gastric cancer tumor size and location. Soft Computing, 24(13):9943-64.
4. Yasui W, Oue N, Aung PP, et al (2005). Molecular-pathological prognostic factors of gastric cancer: a review. Gastric Cancer, 8(2):86-94.
5. Chawla S, Rockstroh A, Lehman M, et al (2022). Gene expression based inference of cancer drug sensitivity. Nat Commun, 13(1):5680.
6. Tyner JW, Haderk F, Kumaraswamy A, et al (2022). Understanding drug sensitivity and tackling resistance in cancer. Cancer Res, 82(8):1448-60.
7. Sisu C (2021). Pseudogenes as Biomarkers Biomarkers and Therapeutic Targets Therapeutic targets in Human Cancers. Methods Mol Biol, 2324:319-337.
8. Xiao-Jie L, Ai-Mei G, Li-Juan J, et al (2015). Pseudogene in cancer: real functions and promising signature. J Med Genet, 52(1):17-24.
9. Hayashi H, Arao T, Togashi Y, et al (2015). The OCT4 pseudogene POU5F1B is amplified and promotes an aggressive phenotype in gastric cancer. Oncogene, 34(2):199-208.
10. Guo X, Deng L, Deng K, et al (2016). Pseudogene PTENP1 suppresses gastric cancer progression by modulating PTEN. Anticancer Agents Med Chem, 16(4):456-64.
11. Emadi-Baygi M, Sedighi R, Nourbakhsh N, et al (2017). Pseudogenes in gastric cancer pathogenesis: a review article. Brief Funct Genomics, 16(6):348-60.
12. Ma H, Ma T, Chen M, et al (2018). The pseudogene-derived long non-coding RNA SFTA1P suppresses cell proliferation, migration, and invasion in gastric cancer. Biosci Rep, 38(2):BSR20171193.
13. Ye J, Li J, Zhao P (2021). Roles of ncRNAs as ceRNAs in Gastric Cancer. Genes (Basel), 12(7):1036.
14. Zhang R, Guo Y, Ma Z, et al (2017). Long non-coding RNA PTENP1 functions as a ceRNA to modulate PTEN level by decoying miR-106b and miR-93 in gastric cancer. Oncotarget, 8(16):26079-26089.
15. Ghafouri-Fard S, Taheri M (2020). Long non-coding RNA signature in gastric cancer. Exp Mol Pathol, 113:104365.
16. Liang L, Zhao K, Zhu JH, et al (2019). Comprehensive evaluation of FKBP10 expression and its prognostic potential in gastric cancer. Oncol Rep, 42(2):615-28.
17. Wang RG, Zhang D, Zhao CH, et al (2020). FKBP10 functioned as a cancer‐promoting factor mediates cell proliferation, invasion, and migration via regulating PI3K signaling pathway in stomach adenocarcinoma. Kaohsiung J Med Sci, 36(5):311-7.
18. Li X, Du Y (2024). Lactate metabolism subtypes analysis reveals CCDC80 as a novel prognostic biomarker in gastric cancer. J Cancer, 15(17):5557-5576.
19. Kong W, Wang Z, Wang B (2023). Unveiling DNA damage repair-based molecular subtypes, tumor microenvironment and pharmacogenomic landscape in gastric cancer. Front Genet, 14:1118889.
20. Qiu T, Zhou X, Wang J, et al (2014). MiR-145, miR-133a and miR-133b inhibit proliferation, migration, invasion and cell cycle progression via targeting transcription factor Sp1 in gastric cancer. FEBS Lett, 588(7):1168-77.
21. Li G, Ao S, Hou J, et al (2019). Low expression of miR‑125a‑5p is associated with poor prognosis in patients with gastric cancer. Oncol Lett, 18(2):1483-90.
22. Hibdon ES, Razumilava N, Keeley TM, et al (2019). Notch and mTOR signaling pathways promote human gastric cancer cell proliferation. Neoplasia, 21(7):702-12.
23. Jaroenlapnopparat A, Bhatia K, Coban S (2022). Inflammation and gastric cancer. Diseases, 10(3):35.
24. Cheng H, Sharen G, Wang Z, et al (2021). LncRNA UCA1 enhances cisplatin resistance by regulating CYP1B1-mediated apoptosis via miR-513a-3p in human gastric cancer. Cancer Manag Res, 13:367-377.
25. Yan H, Zheng C, Li Z, et al (2019). NPTX1 promotes metastasis via integrin/FAK signaling in gastric cancer. Cancer Manag Res, 11:3237- 3251.
26. Zheng S, Shi L, Zhang Y, et al (2014). Expression of SNCG, MAP2, SDF-1 and CXCR4 in gastric adenocarcinoma and their clinical significance. Int J Clin Exp Pathol, 7(10):6606-15.
27. Chen X, Cui Y, Xie X, et al (2018). Functional role of miR-27b in the development of gastric cancer. Mol Med Rep, 17(4):5081-7.
28. Nie H, Mu J, Wang J, et al (2018). miR‑195‑5p regulates multi‑drug resistance of gastric cancer cells via targeting ZNF139. Oncol Rep, 40(3):1370-1378.
29. Wang G, Zhan T, Li F, et al (2021). The prediction of survival in Gastric Cancer based on a Robust 13-Gene Signature. J Cancer, 12(11):3344- 3353.
30. Farah A, Kabbage M, Atafi S, et al (2020). Selective expression of KCNA5 and KCNB1 genes in gastric and colorectal carcinoma. BMC Cancer, 20: 1179.
31. Zhong Q, Wang HG, Yang JH, et al (2023). Loss of ATOH1 in Pit Cell Drives Stemness and Progression of Gastric Adenocarcinoma by Activating AKT/mTOR Signaling through GAS1. Adv Sci (Weinh), 10(32):e2301977.
32. Bao C-h, Guo L (2022). miR-27b-3p inhibits invasion, migration and epithelial-mesenchymal transition in gastric cancer by targeting RUNX1 and activation of the hippo signaling pathway. Anticancer Agents Med Chem, 22(5):864-873.
33. Zhang Y, Wen X, Hu X, et al (2016). Downregulation of miR-145-5p correlates with poor prognosis in gastric cancer. Eur Rev Med Pharmacol Sci, 20(14):3026-30.
| Files | ||
| Issue | Vol 54 No 5 (2025) | |
| Section | Original Article(s) | |
| DOI | https://doi.org/10.18502/ijph.v54i5.18642 | |
| Keywords | ||
| Gene expression ceRNAs network MicroRNAs Pseudogenes | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
